The Lymphoma Channel

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by Takeda) and Morphosys. These supporters have no influence over the production of the content.

Latest Videos Types Subtypes The Lymphoma Sessions Expert Presentations Conferences Features Podcasts Expert Editorial Board

Welcome to The Lymphoma Channel

VJHemOnc brings you the latest updates in lymphoma, directly from the experts. Alongside our world-leading Editorial Board, The Lymphoma Channel covers all of the latest updates in lymphoma presented at international congresses – including video interviews, podcasts and roundtable discussions.

Dive into The Lymphoma Channel to learn more about the latest advances in therapy, including CAR-T, antibody-drug conjugates, checkpoint inhibitors and targeted therapies. As well as updates in therapy, The Lymphoma Channel also covers the latest research in biomarkers, treating relapsed disease, optimal patient selection and more.

Types

Hodgkin
Aggressive
& Diffuse Large
B-Cell
Mantle Cell
Indolent
B-Cell
Aggressive
T-Cell &
NK-Cell
Cutaneous
6:40
Lymphoma & myeloma abstract highlights: LV20.19 CAR-T in MCL, Pano/GemBuMel in R/R myeloma & more
Swetha Kambhampati • 23 Feb 2023
1:58
Incorporating immunotherapy in the frontline & salvage treatment of Hodgkin lymphoma
Swetha Kambhampati • 23 Feb 2023
1:16
Dual-targeting CD30/PDL1 CAR-T therapy in Hodgkin lymphoma
Vincenzo Perriello • 10 Feb 2023
2:14
Long-term follow-up results from the RATHL trial: response-adapted treatment for advanced stage HL
Stefano Luminari • 12 Dec 2022
View All Videos
3:43
Efficacy of mosunetuzumab monotherapy in elderly/unfit patients with previously untreated DLBCL
Adam Olszewski • 12 Dec 2022
1:01
Impact of specific comorbidities on the outcome of patients with DLBCL treated with CAR-T therapy
Geoffrey Shouse • 12 Dec 2022
1:28
How the standard of care for DLBCL is changing with the introduction of novel agents
Wendy Osborne • 10 Feb 2023
2:14
Treatment options for patients with DLBCL who relapse after CAR-T therapy
Wendy Osborne • 10 Feb 2023
View All Videos
1:27
Acalabrutinib in combination with umbralisib and ublituximab in previously untreated MCL
Geoffrey Shouse • 12 Dec 2022
1:46
Exploring the use of BTK inhibitors as a strategy to increase the efficacy of CAR-T cells
John Gribben • 10 Feb 2023
12:00
Case report: unusual toxicity after treatment with brexu-cel
Jacopo Mariotti • 13 Feb 2023
6:40
Lymphoma & myeloma abstract highlights: LV20.19 CAR-T in MCL, Pano/GemBuMel in R/R myeloma & more
Swetha Kambhampati • 23 Feb 2023
View All Videos
1:22
First-in-human study of TG-1801, a CD19/CD47 bispecific antibody ± ublituximab in BCL
Eliza Hawkes • 12 Dec 2022
1:16
Controversies surrounding the management and treatment of lymphomas
Loretta Nastoupil • 12 Dec 2021
1:43
Late toxicities in non-Hodgkin lymphoma and why they should be studied
Ann LaCasce • 15 Dec 2021
1:22
Safety and efficacy of CC-99282 in the treatment of R/R NHL
Loretta Nastoupil • 12 Dec 2021
View All Videos
2:42
Duvelisib for R/R PTCL: updates from the PRIMO trial
Steven Horwitz • 6 Dec 2020
2:29
TTI-621 for hematologic malignancies: a Phase I dose escalation and expansion study
Steven Horwitz • 6 Dec 2020
2:55
Novel issues in the combined modality treatment of lymphomas
Lena Specht • 14 Jun 2017
View All Videos
3:30
RadVax trial: nivolumab and low-dose radiation in patients with R/R Hodgkin lymphoma
Michael LaRiviere • 11 Dec 2022
2:24
Clonal evolution in patients with CTCL
Neha Mehta-Shah • 9 Dec 2022
1:12
TELLOMAK: lacutamab alone or with chemotherapy in patients with mycosis fungoides or Sézary syndrome
Neha Mehta-Shah • 9 Dec 2022
3:55
The standard of care in T-cell lymphoma: challenges and future outlooks
Swaminathan Iyer • 30 Sep 2022
View All Videos

Subtypes

Burkitt
Diffuse Large
B-Cell
Follicular
Waldenström’s
Peripheral
T-Cell
NK/T-cell
3:10
An analysis of the risk factors associated with disease progression in patients with BL
Mark Roschewski • 14 Dec 2021
4:13
Treating lymphoma in the developing world
Franco Cavalli • 24 Jun 2021
6:46
Diagnosing and treating NHL in teenagers and young adults
Robert Carr • 22 Jun 2021
3:16
Developing the novel Burkitt Lymphoma International Prognostic Index
Adam Olszewski • 8 Dec 2020
View All Videos
3:43
Efficacy of mosunetuzumab monotherapy in elderly/unfit patients with previously untreated DLBCL
Adam Olszewski • 12 Dec 2022
1:01
Impact of specific comorbidities on the outcome of patients with DLBCL treated with CAR-T therapy
Geoffrey Shouse • 12 Dec 2022
1:28
How the standard of care for DLBCL is changing with the introduction of novel agents
Wendy Osborne • 10 Feb 2023
2:14
Treatment options for patients with DLBCL who relapse after CAR-T therapy
Wendy Osborne • 10 Feb 2023
View All Videos
1:05
Evaluating copanlisib in combination with nivolumab in patients with RT or transformed NHL
Geoffrey Shouse • 12 Dec 2022
2:23
Results from the Phase II ELM-2 trial: odronextamab for R/R follicular lymphoma
Stefano Luminari • 12 Dec 2022
3:01
Updates on the use of CAR-T therapy in mantle cell lymphoma and follicular lymphoma
Ulrich Jäger • 10 Feb 2023
3:02
Limitations of current risk stratification systems in FL & treatment options for high-risk patients
Tycel Phillips • 5 Dec 2022
View All Videos
2:51
Pirtobrutinib shows efficacy in BTKi refractory Waldenström’s macroglobulinemia patients
Chan Yoon Cheah • 9 Dec 2022
2:39
Antibody response to COVID-19 vaccine in patients with multiple myeloma and WM
Evangelos Terpos • 10 Dec 2022
1:33
Zanubrutinib in acalabrutinib-intolerant patients with various B-cell malignancies
Mazyar Shadman • 9 Dec 2022
0:57
Investigating the efficacy of CD20 CAR-T cell therapy for WM and CNS lymphoma
Mazyar Shadman • 9 Dec 2022
View All Videos
1:16
Highlights in PTCL at ASH 2022
Neha Mehta-Shah • 9 Dec 2022
1:36
Novel therapeutic regimens being explored in PTCL
Neha Mehta-Shah • 30 Sep 2022
2:01
Potential therapeutic targets in subsets of PTCL
Francisco Vega • 26 Sep 2022
3:22
How novel molecular techniques have improved and are providing more insight into the biology of PTCL
Francisco Vega • 26 Sep 2022
View All Videos
2:04
IMC-001: preliminary results of novel PD-L1 inhibitor for R/R extranodal NK/T cell lymphoma
Won-Seog Kim • 24 Nov 2022
0:42
Approaching NK/T-cell lymphoma
Won-Seog Kim • 11 Jun 2022
1:15
Results of Phase II study of tislelizumab in R/R NK/T-cell neoplasms
Emmanuel Bachy • 11 Jun 2022
3:56
Advances in treating T-cell lymphoma
Franco Cavalli • 24 Jun 2021
View All Videos

Conferences

Tandem Meetings 2023
CAR-T Meeting 2023
ASH 2022
ISHL12 2022
SOHO 2022
EHA 2022
6:01
Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure
Amer Beitinjaneh • 22 Feb 2023
6:40
Lymphoma & myeloma abstract highlights: LV20.19 CAR-T in MCL, Pano/GemBuMel in R/R myeloma & more
Swetha Kambhampati • 23 Feb 2023
3:23
Real-world outcomes of patients with transformed R/R DLBCL treated with CD19 CAR-T therapy
Swetha Kambhampati • 23 Feb 2023
1:58
Incorporating immunotherapy in the frontline & salvage treatment of Hodgkin lymphoma
Swetha Kambhampati • 23 Feb 2023
View All Videos
1:28
How the standard of care for DLBCL is changing with the introduction of novel agents
Wendy Osborne • 10 Feb 2023
2:14
Treatment options for patients with DLBCL who relapse after CAR-T therapy
Wendy Osborne • 10 Feb 2023
0:58
CAR-T therapy in non-Hodgkin lymphoma: current status and future outlooks
Ulrich Jäger • 10 Feb 2023
1:46
Exploring the use of BTK inhibitors as a strategy to increase the efficacy of CAR-T cells
John Gribben • 10 Feb 2023
View All Videos
3:43
Efficacy of mosunetuzumab monotherapy in elderly/unfit patients with previously untreated DLBCL
Adam Olszewski • 12 Dec 2022
1:27
Acalabrutinib in combination with umbralisib and ublituximab in previously untreated MCL
Geoffrey Shouse • 12 Dec 2022
1:01
Post-ibrutinib relapse outcomes for patients with marginal zone lymphoma
Geoffrey Shouse • 12 Dec 2022
1:01
Impact of specific comorbidities on the outcome of patients with DLBCL treated with CAR-T therapy
Geoffrey Shouse • 12 Dec 2022
View All Videos
0:51
The value of CAR-T cell therapy in R/R DLBCL
Peter Borchmann • 25 Oct 2022
2:32
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Paul Jan Bröckelmann • 17 Oct 2022
3:54
The use of TARC as a diagnostic biomarker in Hodgkin lymphoma
Arjan Diepstra • 26 Oct 2022
1:19
Using PET-adapted study designs to de-escalate treatment intensity in HL
Peter Borchmann • 25 Oct 2022
View All Videos
3:49
The challenges in developing bispecific antibodies for non-Hodgkin lymphoma
Michael Dickinson • 30 Sep 2022
1:40
Major unmet needs in the MCL patient population
Jonathon Cohen • 7 Oct 2022
1:36
Novel therapeutic regimens being explored in PTCL
Neha Mehta-Shah • 30 Sep 2022
1:24
The current understanding and approach to breast implant-associated anaplastic large cell lymphoma
Neha Mehta-Shah • 30 Sep 2022
View All Videos
4:06
The impact of RBPs in the development of hematological malignancies and bone marrow failure
Miguel Gallardo • 23 Jun 2022
1:03
The importance of circulating tumor DNA in patients with primary CNS lymphoma
Won-Seog Kim • 11 Jun 2022
0:42
Approaching NK/T-cell lymphoma
Won-Seog Kim • 11 Jun 2022
1:05
Updates on tafasitamab for the treatment of DLBCL
Wojciech Jurczak • 11 Jun 2022
View All Videos

Topics

MRD
CAR-T & Cellular
Therapy
Trial Updates
Real-World Data
Immuno-Oncology
Transplant
8:37
Safety and efficacy of CD7-targeted CAR-T therapy in patients with R/R T-ALL and T-LBL
Peihua Lu • 12 Dec 2022
7:35
Survey on the evaluation and management of DLBCL following suboptimal response to CAR-T therapy
Nausheen Ahmed • 20 Feb 2023
5:12
Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCL
Jia Ruan • 10 Dec 2022
2:32
The use of PET and ctDNA for risk stratification & to guide treatment decisions in Hodgkin lymphoma
Peter Borchmann • 12 Dec 2022
View All Videos
6:01
Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure
Amer Beitinjaneh • 22 Feb 2023
1:01
Impact of specific comorbidities on the outcome of patients with DLBCL treated with CAR-T therapy
Geoffrey Shouse • 12 Dec 2022
1:28
How the standard of care for DLBCL is changing with the introduction of novel agents
Wendy Osborne • 10 Feb 2023
2:14
Treatment options for patients with DLBCL who relapse after CAR-T therapy
Wendy Osborne • 10 Feb 2023
View All Videos
3:43
Efficacy of mosunetuzumab monotherapy in elderly/unfit patients with previously untreated DLBCL
Adam Olszewski • 12 Dec 2022
1:27
Acalabrutinib in combination with umbralisib and ublituximab in previously untreated MCL
Geoffrey Shouse • 12 Dec 2022
6:01
Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure
Amer Beitinjaneh • 22 Feb 2023
1:05
Evaluating copanlisib in combination with nivolumab in patients with RT or transformed NHL
Geoffrey Shouse • 12 Dec 2022
View All Videos
12:00
Case report: unusual toxicity after treatment with brexu-cel
Jacopo Mariotti • 13 Feb 2023
3:23
Real-world outcomes of patients with transformed R/R DLBCL treated with CD19 CAR-T therapy
Swetha Kambhampati • 23 Feb 2023
4:49
Clinical features and long-term outcomes of autoSCT & alloSCT in R/R DLBCL between 1990 and 2019
Anna Sureda • 3 Jan 2023
4:32
Retrospective analysis on the role of allogeneic transplantation in 3L B-NHL in the CAR-T era
Anna Sureda • 3 Jan 2023
View All Videos
3:43
Efficacy of mosunetuzumab monotherapy in elderly/unfit patients with previously untreated DLBCL
Adam Olszewski • 12 Dec 2022
1:27
Acalabrutinib in combination with umbralisib and ublituximab in previously untreated MCL
Geoffrey Shouse • 12 Dec 2022
6:01
Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure
Amer Beitinjaneh • 22 Feb 2023
1:01
Impact of specific comorbidities on the outcome of patients with DLBCL treated with CAR-T therapy
Geoffrey Shouse • 12 Dec 2022
View All Videos
1:27
Acalabrutinib in combination with umbralisib and ublituximab in previously untreated MCL
Geoffrey Shouse • 12 Dec 2022
6:01
Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure
Amer Beitinjaneh • 22 Feb 2023
2:23
Patient selection for autoSCT in HL & increasing CR rate before autoSCT with novel salvage regimens
Sanjal Desai • 21 Feb 2023
2:00
The use of chemotherapy in R/R Hodgkin and non-Hodgkin lymphomas
Sanjal Desai • 21 Feb 2023
View All Videos

The Lymphoma Channel on VJHemOnc is supported by Takeda) and Morphosys.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us

VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals